X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1751) 1751
male (1410) 1410
index medicus (1221) 1221
hiv infections - drug therapy (1206) 1206
female (994) 994
anti-hiv agents - therapeutic use (881) 881
benzoxazines (856) 856
benzoxazines - therapeutic use (849) 849
pharmacology & pharmacy (810) 810
adult (780) 780
animals (745) 745
infectious diseases (622) 622
reverse transcriptase inhibitors - therapeutic use (610) 610
efavirenz (596) 596
benzoxazines - pharmacology (546) 546
oxazines - therapeutic use (495) 495
middle aged (488) 488
hiv (473) 473
morpholines - pharmacology (458) 458
naphthalenes - pharmacology (456) 456
rats (428) 428
drug therapy, combination (406) 406
immunology (359) 359
benzoxazines - administration & dosage (357) 357
neurosciences (352) 352
treatment outcome (342) 342
viral load (337) 337
hiv infections - virology (329) 329
anti-hiv agents - adverse effects (304) 304
antiviral agents (301) 301
antiretroviral therapy (297) 297
benzoxazines - adverse effects (293) 293
nevirapine - therapeutic use (288) 288
cd4 lymphocyte count (287) 287
dose-response relationship, drug (285) 285
hiv-1 - drug effects (267) 267
virology (248) 248
anti-hiv agents - administration & dosage (247) 247
mice (245) 245
drug therapy (234) 234
analysis (233) 233
hiv infection (233) 233
lamivudine - therapeutic use (227) 227
therapy (225) 225
nevirapine (222) 222
benzoxazines - pharmacokinetics (220) 220
antiretroviral therapy, highly active (219) 219
drug interactions (210) 210
reverse transcriptase inhibitors - adverse effects (207) 207
microbiology (201) 201
pharmacokinetics (194) 194
hiv protease inhibitors - therapeutic use (193) 193
time factors (189) 189
hiv-1 (188) 188
piperidines - pharmacology (188) 188
pyrazoles - pharmacology (188) 188
rats, sprague-dawley (187) 187
article (182) 182
antiretroviral drugs (176) 176
highly active antiretroviral therapy (176) 176
human immunodeficiency virus--hiv (169) 169
adolescent (168) 168
cannabinoids - pharmacology (168) 168
research (167) 167
anti-hiv agents - pharmacokinetics (166) 166
hiv-1 - genetics (163) 163
tenofovir (162) 162
young adult (162) 162
aged (160) 160
oxazines - adverse effects (160) 160
rats, wistar (158) 158
hiv infections - complications (157) 157
reverse transcriptase inhibitors - administration & dosage (157) 157
cannabinoids (152) 152
protease inhibitors (150) 150
aids (149) 149
adenine - analogs & derivatives (147) 147
disease models, animal (145) 145
ritonavir - therapeutic use (144) 144
health aspects (140) 140
pharmacology (139) 139
zidovudine - therapeutic use (137) 137
care and treatment (136) 136
prospective studies (132) 132
rna, viral - blood (132) 132
adenine - therapeutic use (131) 131
receptor, cannabinoid, cb1 - agonists (131) 131
treatment failure (127) 127
cannabinoid (126) 126
dosage and administration (123) 123
aids/hiv (122) 122
hiv infections - immunology (122) 122
virus diseases (122) 122
anti-hiv agents - pharmacology (121) 121
hiv infections - blood (120) 120
lamivudine (119) 119
benzoxazines - blood (117) 117
drug administration schedule (117) 117
child (116) 116
cohort studies (116) 116
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2374) 2374
French (25) 25
German (21) 21
Spanish (13) 13
Chinese (5) 5
Dutch (4) 4
Italian (4) 4
Russian (2) 2
Czech (1) 1
Hungarian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 229 - 237
Summary Background The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ZIDOVUDINE | COMBINATION THERAPY | ACTIVE ANTIRETROVIRAL THERAPY | EMTRICITABINE | PROTEASE-INHIBITOR | CYSTATIN-C | CREATININE | DAILY LAMIVUDINE | NEVIRAPINE | TENOFOVIR | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Nucleotides - therapeutic use | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Nucleosides - therapeutic use | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Benzoxazines - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Evaluation | Patient outcomes | Clinical trials | Dosage and administration | Drug therapy | HIV infection | Design | Antiretroviral drugs | Corporate sponsorship | Human immunodeficiency virus--HIV | Technological change | Research | Clinical medicine | Drugs | RNA-directed DNA polymerase | Exanthema | antiretroviral therapy | Lamivudine | Lipids | Nucleotides | Regression analysis | Efavirenz | CD4 antigen | nucleosides | Algorithms | Hospitals | non-nucleoside reverse transcriptase inhibitors | Abacavir | Zidovudine | Pharmaceuticals
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | COMBINATION THERAPY | GUIDELINES | PROTEASE-INHIBITOR | ANTIRETROVIRAL THERAPY | NEVIRAPINE | REGIMENS | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 05/2013, Volume 63, Issue 1, pp. 77 - 85
BACKGROUND:STARTMRK, a phase III noninferiority trial of raltegravir-based versus efavirenz-based therapy in treatment-naive patients, remained blinded until... 
raltegravir | HIV | STARTMRK | efavirenz | treatment naive | INFECTIOUS DISEASES | THERAPY | IMMUNOLOGY | HIV-1 INFECTION | SUBGROUP | Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | HIV-1 | Oxazines | Humans | Male | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | Raltegravir Potassium | Emtricitabine | Pyrrolidinones - adverse effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Pyrrolidinones - therapeutic use | Benzoxazines - adverse effects | Treatment Outcome | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Drug Combinations
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 10/2008, Volume 198, Issue 8, pp. 1113 - 1122
Background. Vicriviroc (VCV) is a CCR5 antagonist with nanomolar activity against human immunodeficiency virus (HIV) replication in vitro and in vivo. We... 
HIV/AIDS | Tropisms | RNA | HIV | Placebos | Viruses | AIDS | Infections | Dosage | HIV 1 | Virology | INFECTIOUS DISEASES | MYOCARDIAL-INFARCTION | MICROBIOLOGY | IMMUNOLOGY | HUMAN-IMMUNODEFICIENCY-VIRUS | PROGNOSTIC VALUE | CCR5 ANTAGONIST | INDIVIDUALS | ANTIRETROVIRAL-DRUG-RESISTANCE | SYNCYTIUM-INDUCING PHENOTYPE | EPIDEMIOLOGY | DISEASE PROGRESSION | Piperazines - administration & dosage | Lamivudine - administration & dosage | Humans | Male | RNA, Viral - blood | Reverse Transcriptase Inhibitors - administration & dosage | Viral Load | Zidovudine - administration & dosage | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Reverse Transcriptase Inhibitors - adverse effects | HIV-1 - physiology | Lamivudine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | CCR5 Receptor Antagonists | Benzoxazines - administration & dosage | Double-Blind Method | Zidovudine - adverse effects | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | HIV Infections - virology | Benzoxazines - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Piperazines - therapeutic use | Piperazines - adverse effects | Benzoxazines - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | HIV Infections - drug therapy | Zidovudine - therapeutic use | Lamivudine | Dosage and administration | HIV (Viruses) | Drug therapy | Zidovudine | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9692, pp. 796 - 806
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2013, Volume 3, Issue 3, p. CD005481
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2006, Volume 354, Issue 3, pp. 251 - 260
Journal Article
Journal Article
ANNALS OF INTERNAL MEDICINE, ISSN 0003-4819, 04/2011, Volume 154, Issue 7, p. 445
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 2013, Volume 158, Issue 2, pp. 84 - 92
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 02/2013, Volume 57, Issue 2, pp. 1019 - 1024
Journal Article